Cullinan Therapeutics, Inc. CGEM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $187.4M+31.1% | $142.9M-3.5% | $148.16M+61.1% | $91.95M+59.2% | ||
| $54.25M+0.4% | $54.02M+27.1% | $42.49M+5.7% | $40.19M+37.9% | ||
| $241.65M+22.7% | $196.92M+3.3% | $190.65M+44.3% | $132.14M+52.1% | ||
| -$241.65M-22.7% | -$196.92M-3.1% | -$191.09M— | —— | ||
| -$443K-116% | -$205K— | —— | $57K— | ||
| -$219.88M-31.4% | -$167.38M-9.3% | -$153.16M— | —— | ||
| —— | —— | -$3.69— | —— | ||
| -$241.34M-22.7% | -$196.61M-3.1% | -$190.78M— | —— | ||
| -$241.65M-22.7% | -$196.92M-3.1% | -$191.09M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Cullinan Therapeutics, Inc. profitable?
- Cullinan Therapeutics, Inc. is not currently profitable: it reported a net loss of $221.0M over the trailing twelve months, a -346.1% net margin.
- What is Cullinan Therapeutics, Inc.'s earnings per share?
- Cullinan Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.84.
- Where does Cullinan Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.